Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
27 Results for "
GPR35 agonist
" in MedChemExpress (MCE) Product Catalog:
Products (27)
27 Results for "GPR35 agonist" in MCE Product Catalog:
11
11 Publications Verification
Synonyms: Quinurenic acid
Category:
Alkaloids Human Gut Microbiota Metabolites Neurological Disease Quinoline Alkaloids Endogenous metabolite Disease Research Fields Endocrinology
Target:
11
Category:
Alkaloids Quinoline Alkaloids Endogenous metabolite Disease Research Fields Inflammation/Immunology
Target:
5
Research Areas:
Pamoic acid (Embonic acid) is a potent GPR35 agonist with an EC50 of 79 nM. Pamoic acid exhibits neuroprotective and anti-inflammatory properties .
4
4 Cited Publications
Cat. No.: HY-W010907
CAS No.: 6640-22-8
Research Areas:
Pamoic acid disodium is a potent GPR35 agonist with an EC50 value of 79 nM. Pamoic acid disodium induces GPR35 internalization and activates ERK1/2 with EC50 values of 22 nM and 65 nM, respectively. Pamoic acid disodium potently recruits β-arrestin2 to GPR35 and has an antinociceptive effect .
3
Target:
Research Areas:
Zaprinast (M&B 22948) is a selective inhibitor of cGMP-selective Phosphodiesterase (PDE5). Zaprinast causes a significant increase in cGMP levels in myocytes. Zaprinast is a G protein-coupled receptor 35 (GPR35) agonist which activates rat GPR35 strongly and activates human GPR35 moderately. Zaprinast reduces vessel remodeling through antiproliferative and proapoptotic effects .
2
2 Cited Publications
Synonyms: Quinurenic acid-d5
Cat. No.: HY-W018158
CAS No.: 4790-08-3
Synonyms: 5,6-Dihydroxyindole-2-carboxylic acid
Research Areas:
DHICA (5,6-Dihydroxyindole-2-carboxylic acid) is an eumelanin building block, GPR35 agonist and melanin synthesis intermediate. DHICA activates GPR35, triggering dynamic mass redistribution and β-arrestin translocation. DHICA interacts with DNA and interferes with Fpg activity . DHICA promotes the generation of single-strand breaks in plasmid DNA. DHICA increases the activity and expression levels of SOD and Catalase. DHICA is applicable to research related to skin cancer and colon cancer .
Research Areas:
GPR35 agonist 2 (compound 11) is a potent agonist of GPR35, with EC50s of 26 and 3.2 nM in the β-arrestin and Ca 2+ release assay, respectively .
Cat. No.: HY-100806R
CAS No.: 492-27-3
Synonyms: Quinurenic acid (Standard)
Research Areas:
GPR35 agonist 1 (compound 50) is a potent and specific G protein-coupled receptor-35 (GPR35)/CXCR8 agonist with an EC50 of 5.8 nM, displays good agentgability .
Synonyms: CID2440433
Target:
Research Areas:
ML-184 (CID244033) is a selective GPR55 agonist with an EC50 of 250 nM, more than 100-fold selectivity for GPR55 over GPR35, CB1, and CB2. ML-184 induces ERK1/2 phosphorylation and PKCβII translocation to the plasma membrane via activation of GPR55. ML-184 (CID2440433) increases the proliferation of neural stem cells and promotes neuronal differentiation in vitro .
Cat. No.: HY-16639
CAS No.: 1448895-09-7
Target:
Research Areas:
ML314 is a potent, BBB-penetrant and β-arrestin biased molecule agonist of NTR1 (EC50 = 1.9 μM). ML314 shows good selectivity against NTR2 and GPR35, but does not stimulate Ca2+ mobilization. ML314 can attenuate amphetamine-like hyperlocomotion in dopamine transporter knockout mice. ML314 attenuates methamphetamine-associated hyperlocomotion and potentiates the psychostimulant inhibitory effects of a ghrelin antagonist in wild type mouse model. ML314 also acts as an allosteric enhancer of endogenous neurotensin. ML314 antagonizes G protein signaling. ML314 can be studied in research for methamphetamine abuse conditions .
GPR35 agonist 4 (compound 10) is a potent GPR35 agonist with an pEC50 of 5.86. GPR35 agonist 4 shows high potency human and rat GPR35. Mutation of arginine 3.36 eliminates agonist function of GPR35 agonist 4 .
Cat. No.: HY-W018158R
CAS No.: 4790-08-3
Synonyms: 5,6-Dihydroxyindole-2-carboxylic acid (Standard)
Target:
Reference Standards Endogenous Metabolite GPR35 Arrestin DNA/RNA Synthesis Drug Intermediate SOD
Research Areas:
DHICA (Standard) is an analytical standard of DHICA (HY-W018158). This product is for research and analytical applications. DHICA (5,6-Dihydroxyindole-2-carboxylic acid) is an eumelanin building block, GPR35 agonist and melanin synthesis intermediate. DHICA activates GPR35, triggering dynamic mass redistribution and β-arrestin translocation. DHICA interacts with DNA and interferes with Fpg activity . DHICA promotes the generation of single-strand breaks in plasmid DNA. DHICA increases the activity and expression levels of SOD and Catalase. DHICA is applicable to research related to skin cancer and colon cancer .
Target:
Research Areas:
Bufrolin is a Cromoglycate (histamine release inhibitor) analog and a high potency agonist of GPR35. Bufrolin promotes interactions between β-arrestin-2 and either human GPR35a or rat GPR35. Bufrolin also serves as antiallergic mast cell stabilizer and inhibit an anti-inflammatory response inducible by the internalization peptide. Bufrolin acts as an anti-inflammatory agent to be used in research of delivering pharmacol linked with internalization peptide .
GPR35 agonist 5 (3,5-dinitro-bisphenol A; compound 6) is a weak GPR35 agonist. GPR35 agonist 5 arrests CHO-S cells at the G1/Gophase .
Target:
GPR35 agonist 3 is a synthetic GPR35 agonist with an EC50value of 1.4 μM. GPR35 agonist 3 can be used for the research of various diseases, such as gastric cancer, type 2 diabetes, cardiovascular diseases, immune system and peripheral nervous system .
Cat. No.: HY-W1058476
CAS No.: 1443367-20-1
Research Areas:
GPR35 agonist 6 is a potent and selective agonist targeting GPR35, with an EC50 of 12.1 nM against human GPR35. GPR35 agonist 6 activates the human splice variant GPR35b with comparable efficacy, showing an EC50 of 22.1 nM. GPR35 agonist 6 also exhibits weak GPR55 antagonistic activity, with an IC50 of 21.7 μM, and its agonistic activity towards GPR35 is significantly stronger than its antagonistic activity towards GPR55. GPR35 agonist 6 initiates GPR35 downstream signaling by inducing β-arrestin recruitment. GPR35 agonist 6 is used to investigate GPR35-mediated diseases, such as gastrointestinal lesions and gastric cancer .
Cat. No.: HY-187384
Target:
Research Areas:
GPR35 agonist 7 is a selective GPR35 agonist, with an EC50 of 0.030 μM for hGPR35 and an EC50 of 0.021 μM for mGPR35. GPR35 agonist 7 reduces lipid accumulation. In a high-fat diet-induced MASH mouse model, GPR35 agonist 7 improves hepatic steatosis, corrects lipid metabolism disorders, alleviates hepatic inflammation and attenuates hepatic fibrosis. GPR35 agonist 7 can be used for the research of metabolic dysfunction-associated steatohepatitis .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
